Michael Gibbs, MD
Clinical Neurophysiology · Santa Barbara, CANPI 1063704641
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations.
Across 85 payments — averaging $29.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$408
- AbbVie$387
- Neurelis, Inc.$234
- Jazz Pharmaceuticals Inc.$227
- Neuropace, Inc.$219
- Biogen$148
- plus $850 from 17 others
What the payments were for
- Food & beverage$2,472100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 6 | $408 |
| AbbVie | 21 | $387 |
| Neurelis, Inc. | 4 | $234 |
| Jazz Pharmaceuticals Inc. | 7 | $227 |
| Neuropace, Inc. | 4 | $219 |
| Biogen | 10 | $148 |
| Sunovion Pharmaceuticals Inc. | 2 | $113 |
| MDD US Operations, LLC | 4 | $109 |
| Sumitomo Pharma America, Inc. | 5 | $92 |
| UCB, Inc. | 4 | $91 |
| Monteris Medical Corporation | 2 | $68 |
| EMD Serono, Inc. | 2 | $55 |
| Catalyst Pharmaceuticals, Inc. | 2 | $49 |
| Ceribell, Inc. | 2 | $40 |
| Zimmer Biomet | 1 | $36 |
| Livanova USA, Inc. | 2 | $32 |
| Argenx US, Inc. | 1 | $32 |
| Biohaven Pharmaceuticals, Inc. | 1 | $29 |
| Medtronic | 1 | $29 |
| Lundbeck LLC | 1 | $27 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Pfizer | 1 | $15 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,472 in reported general payments places this provider in the 60th percentile of 49 clinical neurophysiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 98 | $104,983 |
| TecfideraDimethyl Fumarate | 12 | $104,049 |
| CopaxoneGlatiramer Acetate | 13 | $70,957 |
| FycompaPerampanel | 38 | $67,933 |
| EpidiolexCannabidiol (Cbd) | 25 | $67,700 |
| Nurtec OdtRimegepant Sulfate | 44 | $61,641 |
| Lacosamide | 434 | $55,808 |
| QuliptaAtogepant | 52 | $55,001 |
| LamictalLamotrigine | 22 | $53,610 |
| NayzilamMidazolam | 25 | $48,966 |
| XcopriCenobamate | 39 | $47,056 |
| AptiomEslicarbazepine Acetate | 24 | $44,874 |
| RytaryCarbidopa/Levodopa | 32 | $43,237 |
| ValtocoDiazepam | 37 | $40,830 |
| Clobazam | 153 | $40,788 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera | $148 | $104,04912 claims |
| UCB, Inc.Nayzilam, Vimpat, Briviact | $91 | $96,56452 claims |
| AbbVieQulipta, Ubrelvy | $387 | $84,78780 claims |
| PfizerNurtec Odt, Eliquis | $15 | $70,62758 claims |
| SK Life Science, Inc.Xcopri | $408 | $47,05639 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $113 | $44,87424 claims |
| Neurelis, Inc.Valtoco | $234 | $40,83037 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 49 clinical neurophysiology providers in California.
Other clinical neurophysiology in Santa Barbara
- Said BeydounLos Angeles$985K
- Christopher LockStanford$159K
- Srikanth MuppidiStanford$150K
- Mitchell MiglisStanford$51K
- Michael AminoffSan Francisco$41K
- Safwan JaradehStanford$34K
- Sadiq AltamimiPomona$30K
- Margaret FerrisStanford$18K
- Kathleen PostonStanford$18K
- Alexander GevorgyanGlendale$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.